Clinical trial
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent…
NCT00433381 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00433381 |
|---|---|
| Title | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma |
| Official title | A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | American College of Radiology Imaging Network Radiation Therapy Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm |
| Intervention type | Biological, Drug |
| Interventions | Bevacizumab, Irinotecan Hydrochloride, Temozolomide |
| Enrollment | 123 |
| Start date | Mar 1, 2007 |
| Primary completion | Jan 21, 2010 |
| Completion | Feb 16, 2011 |
| First posted | Feb 12, 2007 |
| Last update posted | Sep 17, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: